Global Immunoglobulin Market to Grow at a CAGR of 7.1% During 2024-2032, Aided by Improving Technology in the Healthcare Sector

Among all the regional markets for immunoglobulin, North America accounted for the largest share of the global market. This trend is expected to be maintained over the forecast period due to the hefty expenditure in the healthcare sector facilitating rapid development for antibody therapy. The market in the region witnessed a peak rise during the onset of the coronavirus pandemic, with all the stakeholders conducting over 50 various clinical trials using antibody therapy. Additionally, presence of the several plasma production facilities in the region is a significant factor responsible for propelling the market growth.

Immunoglobulins are administered to patients via the intravenous and subcutaneous routes. The market share occupied by the intravenous segment is a few folds larger than that of the subcutaneous segment. This can be attributed to the high availability of products in this segment and rapid absorption in the patient body during treatment. Intravenous mode of delivery is expected to continue the growth trend in the coming years, aided by several approvals for Intravenous Immunoglobin (IVIg) over the years. Furthermore, hypogammaglobulinemia is estimated to occupy a major share in the global market owing to the noteworthy rise in the prevalence of the associated disorder in recent years.

In September 2020, Biotest AG (ETR: BIO) announced the completion of its study involving 67 patients, including 18 children, for the investigation of IgG Next Generation as replacement therapy in patients diagnosed with primary immunodeficiency disease (PID), a group of disorders in which a part of the body's immune system does not function properly. Moreover, in November 2020, Eli Lilly and Company (NYSE: LLY), an American pharmaceutical company, received emergency use authorisation from the Food and Drug Administration (U.S.A.) for the neutralising antibody bamlanivimab (LY-CoV555). These developments in the industry are expected to further the market growth over the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Application, Route of Administration, Clinical Trial, and Region:

• The market, on the basis of application, can be divided into hypogammaglobulinemia, CIPD, immunodeficiency diseases, congenital AIDS, chronic lymphocytic leukaemia, myasthenia gravis, multifocal motor neuropathy, ITP, Kawasaki disease, and Guillain-Barre syndrome.

• Based on route of administration, the industry can be divided into intravenous and subcutaneous.

• The clinical trial segment for immunoglobulin includes IgG, IgA, IgM, IgE, and IgD.

• The regional markets for immunoglobulin include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The rise in the prevalence of immunodeficiency and neurological disorders is a significant driving force for the demand growth for immunoglobulin, further aiding the market.

• The market growth is augmented by the emergence of enhanced purification techniques that offer a better yield of plasma.

• The rising demand for cancer diagnostics which utilises spatial genomic analysis, aided by immunoglobulins, is expected to boost the market growth.

• Improvements in the research and development sector for the creation of new products for the control of diseases is expected to drive market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for immunoglobulin for the periods (2018-2023) and (2024-2032).

• The report also offers the historical (2018-2023) and forecast (2024-2032) markets for the applications, routes of administration, clinical trials, and regions of immunoglobulin.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global immunoglobulin market are Biotest AG, Octapharma AG, Baxter International Inc., China Biologics Products Inc., and Grifols SA, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.